PL2019965T3 - Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego - Google Patents

Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego

Info

Publication number
PL2019965T3
PL2019965T3 PL07761742T PL07761742T PL2019965T3 PL 2019965 T3 PL2019965 T3 PL 2019965T3 PL 07761742 T PL07761742 T PL 07761742T PL 07761742 T PL07761742 T PL 07761742T PL 2019965 T3 PL2019965 T3 PL 2019965T3
Authority
PL
Poland
Prior art keywords
pulmonary
cardiovascular disease
differential diagnosis
diagnosis
differential
Prior art date
Application number
PL07761742T
Other languages
English (en)
Inventor
James V Snider
Sven Jacobson
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Publication of PL2019965T3 publication Critical patent/PL2019965T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Brain natriuretic peptide [BNP, proBNP]; Cardionatrin; Cardiodilatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
PL07761742T 2006-05-02 2007-05-02 Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego PL2019965T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79728506P 2006-05-02 2006-05-02
EP07761742.1A EP2019965B1 (en) 2006-05-02 2007-05-02 Differential diagnosis between pulmonary and cardiovascular disease
PCT/US2007/068024 WO2007131031A2 (en) 2006-05-02 2007-05-02 Diagnosis of pulmonary and/or cardiovascular disease

Publications (1)

Publication Number Publication Date
PL2019965T3 true PL2019965T3 (pl) 2015-10-30

Family

ID=38668508

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07761742T PL2019965T3 (pl) 2006-05-02 2007-05-02 Rozpoznawanie różnicowe chorób układu oddechowego i sercowo-naczyniowego

Country Status (9)

Country Link
US (2) US20100055683A1 (pl)
EP (2) EP2995951B1 (pl)
DK (1) DK2019965T3 (pl)
ES (2) ES2723957T3 (pl)
HU (1) HUE025058T2 (pl)
PL (1) PL2019965T3 (pl)
PT (1) PT2019965E (pl)
SI (1) SI2019965T1 (pl)
WO (1) WO2007131031A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038794A2 (en) 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
ES2573471T3 (es) 2002-05-09 2016-06-08 The Brigham And Women's Hospital, Inc. 1L1RL-1 como un marcador de enfermedades cardiovasculares
ATE476657T1 (de) 2006-04-24 2010-08-15 Critical Care Diagnostics Inc Vorhersage von letalität und detektion von schweren erkrankungen
EP2021799B1 (en) * 2006-04-27 2011-07-20 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
PT2021796E (pt) 2006-05-01 2012-04-19 Critical Care Diagnostics Inc Diagnóstico de doença cardiovascular
EP2995951B1 (en) * 2006-05-02 2019-02-13 Critical Care Diagnostics, Inc. Method for selecting treatment based on differential diagnosis between pulmonary and cardiovascular disease
EP1882945A1 (en) * 2006-07-28 2008-01-30 F.Hoffmann-La Roche Ag Means and methods for the differentiation of cardiac and pulmonary causes of acute shortness of breath
PT2827152T (pt) 2008-04-18 2016-09-13 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
EP2141499A1 (en) 2008-07-02 2010-01-06 Apoptec AG COPD diagnosis
EP2331964A1 (en) * 2008-08-13 2011-06-15 Roche Diagnostics GmbH D-dimer, troponin, nt-probnp for pulmonary embolism
HRP20160461T1 (hr) 2010-04-09 2016-06-17 Critical Care Diagnostics, Inc. Solubilna humana st-2 antitijela i eseji
US8728742B2 (en) 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
EP2734222B1 (en) 2011-07-18 2016-10-19 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
EP2637023A1 (en) * 2012-03-08 2013-09-11 B.R.A.H.M.S GmbH Prediction of outcome in patients with chronic obstructive pulmonary disease
MX357740B (es) 2012-05-18 2018-07-23 Critical Care Diagnostics Inc Métodos para determinar el pronóstico del tratamiento de un sujeto con un desfibrilador cardíaco implantado, un dispositivo de tratamiento de resincronización cardíaca o un dispositivo combinado de desfibrilador cardíaco implantado y de resincronización cardíaca.
PL2885641T3 (pl) 2012-08-16 2018-04-30 Critical Care Diagnostics, Inc. Metody przewidywania ryzyka rozwoju nadciśnienia tętniczego krwi
MX375520B (es) 2012-08-21 2025-03-06 Critical Care Diagnostics Inc Estratificación de riesgo para marcador múltiple.
MX2016009060A (es) 2014-01-10 2016-09-09 Critical Care Diagnostics Inc Metodos y sistemas para determinar el riesgo de falla cardiaca.
US20160168640A1 (en) 2014-11-10 2016-06-16 Genentech, Inc. Therapeutic and diagnostic methods for il-33-mediated disorders
MX2017006094A (es) 2014-11-10 2017-07-19 Genentech Inc Anticuerpos anti-interleucina-33 y sus usos.
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
KR101873499B1 (ko) 2015-02-10 2018-07-03 주식회사 원메디칼 혈관 질환 진단용 바이오 마커 및 이의 용도
EP3582802A4 (en) * 2017-02-17 2021-02-17 The General Hospital Corporation METHODS AND COMPOSITIONS FOR THE TREATMENT OF A BRAIN INJURY
US20190120788A1 (en) * 2017-10-20 2019-04-25 University Of Southern California Systems and methods for fabricating an indium oxide field-effect transistor
CN109633138A (zh) * 2019-01-24 2019-04-16 黑龙江八农垦大学 一种预警奶牛胎衣不下的生物标志物及其应用
EP4118114A1 (en) 2020-03-13 2023-01-18 Genentech, Inc. Anti-interleukin-33 antibodies and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US534879A (en) * 1895-02-26 Device foe packing
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
US5217899A (en) * 1990-08-24 1993-06-08 The General Hospital Corporation Cell stretching apparatus
GB9211686D0 (en) * 1992-06-03 1992-07-15 Medisinsk Innovation A S Chemical compounds
US6066322A (en) * 1995-03-03 2000-05-23 Millennium Pharmaceuticals, Inc. Methods for the treatment of immune disorders
PT1493439E (pt) * 1997-04-02 2012-01-10 Brigham & Womens Hospital Meio de avaliação do perfil de risco de um indivíduo para uma doença aterosclerótica
ATE489633T1 (de) * 1997-06-10 2010-12-15 Lpath Inc Verfahren zum frühzeitigen nachweis herzerkrankungen
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
FR2795823B1 (fr) * 1999-07-01 2001-11-23 Inst Nat Sante Rech Med Methodes et kits pour le diagnostic ou le suivi d'une pathologie synoviale ou osteoarticulaire comprenant l'utilisation d'un marqueur specifique de la degradation du tissu synovial
US6323334B1 (en) * 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
WO2001070817A1 (en) * 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Monoclonal antibody and method and kit for the immunoassay of soluble human st2 with the use of the same
WO2002038794A2 (en) * 2000-11-09 2002-05-16 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US20040253637A1 (en) * 2001-04-13 2004-12-16 Biosite Incorporated Markers for differential diagnosis and methods of use thereof
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
DE60233301D1 (de) * 2001-05-04 2009-09-24 Biosite Inc Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
WO2003022987A2 (en) * 2001-07-26 2003-03-20 Eos Biotechnology, Inc. Methods of diagnosis of hepatitis c infection, compositions and methods of screening for modulators of hepatitis c infection
ES2573471T3 (es) * 2002-05-09 2016-06-08 The Brigham And Women's Hospital, Inc. 1L1RL-1 como un marcador de enfermedades cardiovasculares
AU2003299441A1 (en) * 2002-12-19 2004-07-14 Centre National De La Recherche Scientifique - Cnrs Nf-hev compositions and methods of use
US20040133079A1 (en) * 2003-01-02 2004-07-08 Mazar Scott Thomas System and method for predicting patient health within a patient management system
US20050250156A1 (en) * 2003-10-31 2005-11-10 Shebuski Ronald J Detection of acute myocardial infarction biomarkers
CA3050151C (en) * 2003-11-26 2023-03-07 Celera Corporation Single nucleotide polymorphisms associated with cardiovascular disorders and statin response, methods of detection and uses thereof
NZ549040A (en) * 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
ATE476657T1 (de) * 2006-04-24 2010-08-15 Critical Care Diagnostics Inc Vorhersage von letalität und detektion von schweren erkrankungen
PT2021796E (pt) * 2006-05-01 2012-04-19 Critical Care Diagnostics Inc Diagnóstico de doença cardiovascular
EP2995951B1 (en) * 2006-05-02 2019-02-13 Critical Care Diagnostics, Inc. Method for selecting treatment based on differential diagnosis between pulmonary and cardiovascular disease
US8147817B2 (en) * 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
PT2827152T (pt) * 2008-04-18 2016-09-13 Critical Care Diagnostics Inc Previsão do risco de eventos cardíacos adversos maiores
HRP20160461T1 (hr) * 2010-04-09 2016-06-17 Critical Care Diagnostics, Inc. Solubilna humana st-2 antitijela i eseji
US8728742B2 (en) * 2011-03-17 2014-05-20 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
EP2734222B1 (en) * 2011-07-18 2016-10-19 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy

Also Published As

Publication number Publication date
EP2995951A1 (en) 2016-03-16
DK2019965T3 (en) 2015-07-20
EP2019965A2 (en) 2009-02-04
ES2723957T3 (es) 2019-09-04
EP2995951B1 (en) 2019-02-13
SI2019965T1 (sl) 2015-10-30
ES2542343T3 (es) 2015-08-04
US20100055683A1 (en) 2010-03-04
PT2019965E (pt) 2015-08-28
WO2007131031A3 (en) 2008-10-30
EP2019965B1 (en) 2015-04-15
US20140302536A1 (en) 2014-10-09
EP2019965A4 (en) 2009-12-16
WO2007131031A2 (en) 2007-11-15
HUE025058T2 (en) 2016-01-28

Similar Documents

Publication Publication Date Title
PT2019965E (pt) Diagnóstico diferencial entre doença pulmonar e cardiovascular
IL188231A0 (en) Methods and compositions for diagnosis and monitoring of atherosclerotic cardiovascular disease
IL187859A0 (en) Diagnosis and prognosis of diabetes
EP1888765A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS OF VENOUS THROMBOEMBOLIC ILLNESSES
PL1885383T3 (pl) Kocie probiotyczne bifidobakterie
GB2456813B (en) Diagnostic context construction and comparison
EP2019911A4 (en) PULMONARMATRATZE
EP1970002A4 (en) CUFF OF A BLOOD PRESSURE METER AND BLOOD PRESSURE METER THEREFOR
ZA201001486B (en) Diagnosis,staging and monitoring of inflammatory bowel disease
GB2430045B (en) Multi-spectral imaging
IL172754A0 (en) Urethral blockage diagnosis
IL184343A0 (en) Gitr antibodies for the diagnosis of nsclc
PL2056858T3 (pl) Leczenie stanów chorobowych płuc
IL166183A0 (en) Novel diagnostic and imaging techniques of the gi tract
FR2916969B1 (fr) Kit comprenant des composes x et y fonctionnalises alcoxysilane.
GB0709092D0 (en) Diagnosis and method of disease
EP1870710A4 (en) BIOMARKERS FOR DIAGNOSIS OF DISEASE AND USE THEREOF
GB2415039B (en) Diagnosis and prognosis
FR2916970B1 (fr) Kit comprenant des composes x et y fonctionnalises alpha-alcoxysilane.
GB0613113D0 (en) Nanotubes and nanotube micelles
ZA200710200B (en) Cardiovascular disease therapies
AU3979P (en) Sweet Caroline Sweet Heart Purple Ipomoea batatas
GB0603355D0 (en) Novel serrs chromophores
GB0608508D0 (en) Diagnosis of infectious disease
GB2444960B (en) Combined pseudoscope and hyperscope